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Birth defects are an urgent global health priority. They affect millions of births worldwide. But their
prevalence and impact are largely under-ascertained, particularly in middle- and low-income countries.
Fortunately, a large proportion of birth defects can be prevented. This review examines the global
prevalence and primary prevention methods for major preventable birth defects: congenital rubella
syndrome, folic acid-preventable spina biﬁda and anencephaly, fetal alcohol syndrome, Down syndrome,
rhesus hemolytic disease of the fetus and the newborn; and those associated with maternal diabetes, and
maternal exposure to valproic acid or iodine deﬁciency during pregnancy. Challenges to prevention ef-
forts are reviewed. The aim of this review is to bring to the forefront the urgency of birth defects pre-
vention, surveillance, and prenatal screening and counseling; and to help public health practitioners
develop population-based birth defects surveillance and prevention programs, and policy-makers to
develop and implement science-based public health policies.
 2013 Published by Elsevier Ltd.1. Introduction
Birth defects are one of the leading causes of infant mortality in
the world, contributing to more than 3 million deaths among
children aged <5 years [1]. Their impact is immeasurable, having
life-long health and economic implications for the affected indi-
vidual, the family, and society. Middle- and low-income countries
have twice the prevalence and mortality associated with birth de-
fects compared with developed countries [1]. When addressing
mortality among people aged <50 years, birth defects are among
top contributors.
A recent report on the global burden of disease ranked birth
defects as the 17th most common cause of disability-adjusted life-
years (DALYs), amounting to 39 million DALYs. This came as an
improvement since 1990, when birth defects ranked 13th among
the leading causes of DALYs and contributed to a total of 54 million
DALYs [2]. These statistics indicate that birth defects prevention
efforts in the last two decades were beneﬁcial, and there is a need
to further intensify their surveillance and prevention. Only then can
we achieve maximum reduction in birth defects-associated DALYs
in a global context. Also, there is an increasing consensus on
shifting focus to non-communicable diseases worldwide, which are
now leading the burden of disease and rising in prevalence.idemiology, Rollins School of
oom 4007, Atlanta, GA 30322,
akley).
Elsevier Ltd.Lack of population-based surveillance and prenatal care pro-
grams contributes to gaps in our knowledge of birth defects in the
developing world. Even though they appear to be rare, birth defects
are a major public health priority at a population level. As with
polio and smallpox, many birth defects are preventable and can be
completely eliminated by timely primary prevention.
We have reviewed current literature on a group of major birth
defects that are highly preventable. These birth defects include
congenital rubella syndrome, folic acid-preventable spina biﬁda and
anencephaly, fetal alcohol syndrome, Down syndrome, and rhesus
hemolytic disease of the fetus and newborn. We have also reviewed
birth defects associated with maternal diabetes, those with in-utero
exposures to valproic acid, andmaternal iodinedeﬁciency. Our aim is
to identify their prevalence in the populations and challenges to
primary prevention strategies.Wehope that this reviewwill serve as
a resource to address modiﬁable risk factors for preventable birth
defects and provide an update on current research in the ﬁeld. Public
health practitioners and epidemiologists can use this review as an
update on population-based birth defects surveillance and preven-
tion programs. Our review may be helpful to policy-makers to
implement science-based policies such as mandatory food fortiﬁca-
tion, and universal prenatal screenings and vaccinations.
2. Congenital rubella syndrome
Congenital rubella syndrome is a group of birth defects that result
from maternal infection to rubella virus during pregnancy. Affected
infants suffer with cataracts, hearing loss, congenital heart defects,
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depends on the time at which the fetus is exposed to the infection in
utero, with the highest risk during the ﬁrst trimester. Congenital
rubella syndrome also poses a high risk of transmission from the
affected infantduring theﬁrstyearafter theirbirth, contributing to the
spread of infection to those in their household or close contact. First
identiﬁed in 1941, congenital rubella syndrome has been associated
with a high infant mortality worldwide [3]. Introduction of rubella
vaccination during the early 1970s and effective implementation of
mass vaccination programs in several World Health Organization
(WHO) member countries in recent years has led to about 80%
reduction in rubella cases, and consequently congenital rubella syn-
drome [4]. However, its prevention has not been complete due to
challenges associated with birth and transmission rates in different
countries [5]. Congenital rubella syndrome has been completely
eliminated in the USA as of December 2011 [6], and an ongoing sur-
veillance monitors the success of this program [7], whereas middle-
and low-income countries in Africa, the Western Paciﬁc, and South
East Asia, where the vaccination rates are below 70%, have signiﬁ-
cantly high rates of rubella infections among women of childbearing
age [8]. Because of these gaps in primary prevention, about 120 000
rubella cases still occur each year in theworld [4]. China, Bangladesh,
Poland, Bosnia and Herzegovina, and Ukraine document the highest
proportion of congenital rubella cases, with an estimated total of
100 000 births affected each year [9]. Some of the challenges to total
prevention of congenital rubella syndrome are variability in vaccina-
tioncoveragewithinandbetweencountries.Countrieswithhighbirth
rate require more than 80% vaccine coverage among women of
childbearing age, thus requiring additional vaccination campaigns.
Also, population isolation in low-income countries hinders vaccina-
tion programs [5]. The WHO has strongly urged countries that are
lacking rubella immunization programs to accelerate their efforts to
prevent rubella and congenital rubella syndrome [10]. Complement-
ing current immunizationprogramswith selective rubellavaccination
among girls and young women is recommended [3].
3. Folic acid-preventable spina biﬁda and anencephaly
Folic acid-preventable spina biﬁda and anencephaly (FAPSBA)
are common birth defects affecting the central nervous system. In
spite of unequivocal evidence from controlled trials in 1991 con-
ﬁrming the effectiveness of folic acid in prevention of spina biﬁda
and anencephaly [11], each year about 246 000 cases of FAPSBA
occur globally [1]. Countries that have implementedmandatory folic
acid fortiﬁcation of food have seen a signiﬁcant reduction in the
prevalence of FAPSBA [12e14]. But not all countries implement
mandatory fortiﬁcation policies that promote adequate folic acid by
womenof reproductive age [15]. Bell andOakley [16] haveestimated
the proportion of FAPSBA cases that can be prevented worldwide,
suggesting that 75% of all neural tube defects can be prevented
through folic acid fortiﬁcation, andwhen there is a good coverage of
populationwith access to the country-speciﬁc fortiﬁcationprogram.
Accordingly, less than one-quarter of total preventable cases of
FAPSBAwere prevented worldwide. The number of cases of FAPSBA
prevented have increased from 9% in 2006 [16] to 15% in 2012 [17];
however, more needs to be done to prevent remaining cases, which
amount to 200 000 cases each year globally. There is an urgent need
for those countries with the majority of these cases, such as India
[18] and China [19,20], to implement mandatory folic acid fortiﬁ-
cation policies and to promote consumption among women of
reproductive age. Some countries opt to offer folic acid supplements
to adolescent girls and women, instead of fortifying centrally pro-
cessed food. Such a prevention strategy based on folic acid supple-
ment intake is shown to be effective in only 50% of women who
adhere to the program [21]. It has also been shown that supplementprograms for high-risk womenwith a history of neural tube defect-
affected pregnancy, even if successful, prevent only a small fraction
(2e5%) of FAPSBA [21]. Thus, optimal prevention of FAPSBA is
achievable only through mandatory fortiﬁcation of centrally pro-
cessed food. There are many challenges for mandatory fortiﬁcation
programs in low- and middle-income countries: fortiﬁcation pro-
grams are known to be dynamic and inﬂuenced by industry and
consumptionpatterns, lackof politicalwill to implementmandatory
fortiﬁcation, resistance from the milling industry to purchase and
disseminate folic acid premix in the ﬂour, isolation and individual
dietary practices of communities that limit intake of centrally pro-
cessed ﬂour, and concerns about safety, cost-effectiveness, and
impact on consumer choice. In countries that implement fortiﬁca-
tion, compliance and uptake have to be monitored periodically.
Overall, assessment of serum folate concentrations among women
of reproductive age can serve as an easy and cost-effective way to
identify risk for FAPSBAand implementprimaryprevention Figure1.
4. Fetal alcohol syndrome
Fetal alcohol syndrome is a structural and neurodevelopmental
group of disorders in individuals with prenatal exposure to alcohol.
Those affected suffer lifelong disability, with no cure. There is a wide
variation in the prevalence of fetal alcohol syndromeworldwide, and
numbersof cases have steadily increased in the last decade [22]. In the
USA, the estimated prevalence is 2e7 cases per 1000 live births [23].
Studies fromEurope [24], Africa [25e27], Israel [28], Australia [29,30],
and Russia [31] show a much higher prevalence. The highest preva-
lence todatehasbeen reported fromhigh-alcohol-consuming regions
of South Africa (90 per 1000 births) [32]. The WHO has recently
convened to study theburdenof fetal alcohol syndrome indeveloping
countries using in-school screeners. Worldwide, 5e10% of all preg-
nancies are at risk for alcohol-related birth defects [33,34]. Recent
studies in theUSA showthat almost50%of reproductive-agedwomen
used alcohol, which included about 8% of pregnant women; while
bingedrinking is prevalent in15%ofnon-pregnantwomenand1.4%of
pregnant women [35]. Drinking during pregnancy is also a major
concern in low- and middle-income countries [36e38]. As maternal
alcohol use during pregnancy is frequently under-ascertained during
the prenatal period, this estimate may bemuch higher in reality [39].
Behavioral modiﬁcation among reproductive-agedwomen should be
the central theme in the prevention of fetal alcohol syndrome [40].
Some challenges to prevention of fetal alcohol syndrome include
cultural and societal attitudes concerning alcohol use, women with
high-risk behaviors entering prenatal care late in pregnancy, and lack
of, or inaccessible, preventive and counseling services in several
countries. Addressing barriers such as guilt and embarrassment
among women regarding their alcohol use will also be an important
challenge in assessing the burden [41]. It has been shown that a ma-
jority of health care providers fail to address the effects of alcohol
abuseor todiagnose fetal alcohol syndromedue to lackof trainingand
knowledge [42,43]. Assessment of maternal alcohol use during
pregnancy should become a standard and routine measure to aid in
risk assessment for the fetus and for counseling and treatment of
alcohol use. Finally, an integrated approach should be developed to
provide health, social, and referral services in a culturally adopted
setting to those affected with alcohol-related birth defects.
5. Maternal age and Down syndrome
Down syndrome is themost common chromosomal abnormality
in newborns. Affected individuals have high rates of intellectual
disability and several birth defects. Down syndrome was ﬁrst char-
acterized in the mid-1800s, and advanced maternal age was deter-
mined as themost signiﬁcant risk factor in the early 1930s [44]. Non-
Figure 1. The status of global prevention of folic acid-preventable spina biﬁda and anencephaly, 2012 [17].
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in mothers of advanced age are suggested as probable causes for
Down syndrome [45]. Despite improved knowledge and screening,
about 5400 births in the USA are affectedwith Down syndrome each
year [45]. Theprevalence ofDownsyndromehas increased in the last
two decades, with an increasing trend in delaying childbirth globally
[46]. Middle- and low-income countries record a large proportion of
births to women of advanced age, while reporting twice as many
cases of Down syndrome as developed countries [1,47]. On the con-
trary, countries where family planning is well-promoted show early
and better-spaced pregnancies, and have lower births to women of
advanced maternal age. European countries that have national
screening policies for Down syndrome (within the ﬁrst trimester)
identify a large number of prenatally diagnosed Down syndrome
cases, as compared to countries without such policies [48]. A large
majority of prenatally diagnosed Down syndrome cases (w90%) are
medically terminated. Socio-economic and technological disparities
hinder the success of prenatal screening programs in both developed
and developing countries. Both individual and societal changes that
encourage lowering the age of conception among womenwill serve
as the singlemost cost-efﬁcient andeffective intervention to prevent
Down syndrome in future births. Implementation of universal
screening and counseling (both pre and post conception) is urgently
required in middle- and low-income countries. Improving organi-
zational and cultural factors to reduce variation inprenatal screening
will better contribute towardsDownsyndromeprevention in several
countries [48].
6. Rhesus hemolytic disease of the fetus and newborn
Several red-cell antigens have been identiﬁed in association with
the hemolytic disease of the fetus and the newborn (HDFN). Among
these, antigen RhD is one of the most common. Incompatibility be-
tween RhD-negative mother and RhD-positive fetus during preg-
nancywill result in production of antibodies to the fetal RhD antigens
(also termed as alloimmunization) [49]. Pregnancies complicated by
alloimmunizationhave ahigh risk of fetal andneonatalmorbidity and
mortality in future pregnancies, and in the absence of timely pro-
phylaxis can lead to fetal jaundice, hydrops (requiring intrauterine
transfusions), fetal anemia, and stillbirths in about 2.4 per 1000 live
births [50]. The mortality rate associated with HDFN in a developed
country such as the UK is about 6 per 100 000 live births or 50 deaths
per year [51], and is expected to be much higher among developing
countries. The alloimmunization is completely treatable by early
identiﬁcation and administering anti-D immune globulin to the
expectant mother. Anti-D immune globulin has been in use since the
1960s and has resulted inmarked reduction in the alloimmunization
to RhD antigen in pregnant women [52]. Lacking prophylaxis, it is
estimated that at least one in every six RhD-negative women deliv-
ering an RhD-positive baby would be at risk [53]. To understand the
racial distribution of this burden, w15% of Caucasians, 3e5% of
African-Americans, 8% Asian-Indians, and <1% of Asians have RhD-
negative blood groups [50,54,55]. The prevalence of RhD-negative
blood group in Europeans is relatively high, and varies between 11%
and21%.Forexample, inwesterncountries, as inEnglandandWales, it
isestimated thatw17%of thepregnantwomenareRhD-negative, and,
among these, 59% are at risk for alloimmunization [56]. Non-invasive
methods have gained prominence and have aided signiﬁcantly in the
reduction of the affected cases. However, several limitations exist.
Improper screening for RhD-negative status, limited prenatal care
facilities, and failure of identiﬁcation and treatment with immune
globulin among high-risk pregnancies has contributed to persistence
of the problem around the world. Developed countries have imple-
mented successful screening programs to identify RhD-negative
women early in pregnancy and administer the immune globulins toprevent HDFN; however, there is a wide variation in both screening
methods and clinicalmanagement policies among different countries
[57]. On the other hand, most developing countries lack screening.
According to the March of Dimes, 100% of cases with HDFN can be
prevented by immune prophylaxis [1]. In sub-Saharan Africa the fre-
quency of RhD-negative women is: Nigeria 4.4%, Guinea 4.1%, Kenya
3.9%, western Uganda 3.6%, and Cameroon 2.4%; yet there is limited
prophylaxis available due to several challenges including poor
research, limited access, affordability of anti-D immune globulin, high
prevalence of illegal abortions, and poor documentation of medical
histories on previous pregnancies, all of which are associated with
highratesofHDFN-relatedmorbidityandmortality in the region [58e
63]. In order to achieve reduction in the deaths associatedwithHDFN,
there is an urgent need for prenatal screening for RhD antigens, uni-
versal access of immune prophylaxis to all women who test RhD
negative, better documentation of reproductive histories, and pro-
motion of post-partum prophylaxis to mothers at risk.
7. Maternal diabetes associated birth defects
Maternal insulin-dependent diabetes and adverse glycemic
control in pregnancy has been consistently associated with a high
risk of birth defects in the offspring both in developed and devel-
oping countries [1]. A three-fold increased risk has been noted for
major cardiovascular, renal, and gastrointestinal defects in infants
born to diabetic mothers compared with their counterparts [64e
66]. Overweight and obesity are signiﬁcant predisposing factors
that lead to diabetes, and both children and adults are at risk
worldwide [67]. Despite advances in medical management, birth
defects associated with maternal diabetes are a common occur-
rence. In the USA w100 000 babies are born to diabetic mothers.
The prevalence estimates for diabetes-associated birth defects
range between 2 and 6 per 1000 births in high-income countries,
and are expected to be several times greater in low- and middle-
income countries [1]. Pregnant mothers with higher levels of
HbA1c at conception have a greater risk of delivering a baby with
birth defects as compared to pregnant mothers with normal levels.
Better glycemic control before pregnancy is shown to reduce the
risk signiﬁcantly [68]. Unfortunately, more than one-third of
women of reproductive age with diabetes are unaware of their
condition [69]; this proportion may be incrementally more in
developing countries [70]. However, prevention of diabetes-
associated birth defects is possible [71]. Selectively monitoring
women with juvenile diabetes can be part of the solution. Also,
screening women for high Gamma-hydroxybutyrate (GHb) con-
centration will help identify high-risk pregnancies, and prevention
efforts can be focused accordingly [72]. Both public- and patient-
oriented approaches in lifestyle modiﬁcation are needed. Aware-
ness of diabetes and its pregnancy-related risk must be improved
among women of reproductive age worldwide. Population-based
screening for women with undiagnosed diabetes is also an urgent
need. Challenges exist in terms of feasibility and funding for uni-
versal screening. Africa and South East Asia, which face the highest
burden of diabetes, have a dearth of primary health centers that can
provide oral hypoglycemic agents to pregnant diabetic women [73].
Other challenges include failure to adhere to, or respond to, treat-
ment among those who are on diabetes medications [74]. A multi-
pronged approach with increased awareness among health care
professionals, periodic screening, and management, has been
shown to have a positive impact on prevention [75,76]. As a pri-
mordial prevention, governments should devise health policies
that promote both education and healthy lifestyles. Political will,
advocacy by health care professionals, and involvement from the
community are important next steps to boost prevention of
diabetes-associated birth defects [74].
Box 1
Prevention of congenital malformation and reproductive effect
[100].
1. Rubella vaccination.
2. Folic acid and vitamin B12 supplementation: 400 mg and
6 mg per day.
3. Supplementation of iodide to deficient patients and
populations.
4. Meticulous diabetic control.
5. Competent diagnosis and management of maternal
hypothyroidism.
6. Screening for chromosome abnormalities and genetic
disease.
7. Hepatitis B vaccination for at-risk women.
8. Human immunodeficiency virus screening and
treatment.
9. Screening for Neisseria gonorrhoea, Chlamydia tra-
chomatis, group B streptococcus.
10. Vaccination of patients with group B streptococcus.
11. Maternal phenylalanine management for maternal
phenylketonurics.
12. Management or discontinuation of oral use of antico-
agulants, anticonvulsants, retinoids, thalidomide and
all known teratogens.
13. Recognize that new teratogens can be represented in the
next new drug or chemical exposure: angiotensin-
converting enzyme inhibitors, angiotensin II receptor
blockers,mycophenolate, tumor necrosis factor blockers.
14. Amniocentesis, chorionic villus sampling, maternal
serum monitoring, ultrasound monitoring to diagnose
identifiable genetic diseases and serious birth defects in
order for the parents to be informed about their options.
15. Maternal smoking and alcohol cessation.
16. Obesity control in itself reduces the risk of birth defects
and decreases the risk of developing diabetes.
17. Immunization against known teratogenic infections.
Botulina toxin vaccine for the pregnant mother to pre-
vent infant botulism.
18. Malaria vaccine to prevent malaria in pregnancy which
increases the risk of miscarriage.
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A positive association between valproic acid (an anti-epileptic
drug) taken in early pregnancy and having offspring with spina
biﬁda was ﬁrst shown in the year 1982. This association was highly
signiﬁcant, with a 20-fold increase in risk of spina biﬁda to babies
born to mothers who were exposed to valproic acid in the ﬁrst
trimester compared with those born to mothers who were unex-
posed [77]. Several subsequent studies further conﬁrmed this as-
sociation, along with new ﬁndings of valproic acid teratogenicity in
association with other major birth defects, including cardiac, uri-
nary, and oro-facial defects in the fetus [77e84]. Following these
studies, many countries have revised their prescription guidelines
for women with epilepsy and have recommended judicious use of
valproic acid during pregnancy for epilepsy disorders, advising less
teratogenic forms of anti-epileptic drugs to women of childbearing
age [85e88]. However, other uses of valproic acid, such as for pain,
migraine, andbipolar disordermake themhighly likely to stay in the
market, and be prescribed towomen of childbearing agewithout an
epilepsy indication [89]. There is a high risk of off-label use of this
drug in developing countries. The US Food and Drug Administration
has made valproic acid a class X drug for migraines, where the risks
involved in using valproic acid in pregnantwomen clearly outweigh
potential beneﬁts. Within the USA, it was estimated thatw40 cases
of spina biﬁda have occurred due to valproic acid use [90], and about
4 per 1000 prescriptions are still written for valproic acid for non-
epilepsy conditions [89]. The March of Dimes Global report on birth
defects (2006) indicated that the risk of such exposure is even higher
in developing countries where valproic acid use may be uncon-
trolled and more common compared with more expensive and less
teratogenic anticonvulsive drugs [1,91]. Thus, it becomes an urgent
necessity to educate not only neurologists, but psychiatrists and
other practitioners to eliminate valproic acid prescriptions among
women of childbearing age, and that its use is seldom justiﬁed, for
both epilepsyandnon-epilepsy indications. Additionally, awareness
needs tobebrought bothamong themedical communityandamong
the population about the teratogenic effects of this drug, so women
in developing countries are not exposed to valproic acid.
9. Iodine deﬁciency
Iodine deﬁciency affectsw2 billion people globally and is a large
concern for women of childbearing age. Each year, about 50 million
children are born to iodine-deﬁcientmothers, and about 40% of these
children suffer signiﬁcant intellectual disability [92]. In 2007, the
WHO reported a high prevalence of iodine deﬁciency in both devel-
oped and developing regions of the world, and not just conﬁned to
remoteandmountainousregions,aspreviously thought [93].National
nutritional surveys from the USA estimate that w35% of pregnant
women have at least mild iodine deﬁciency [94]. To address this
problem, the American Thyroid Association recommends 150 mg per
day of iodine intake for pregnant and lactating women, starting early
at preconception [95,96]. Pregnancy confers an increased need for
iodine, [97] and its insufﬁciency has been associated with cretinism,
intellectual delays, birth defects, and other suboptimal outcomes in
the infant [95,98]. Iodinedeﬁciency isalsothemost importantcauseof
preventable intellectual disability in infants worldwide [96]. Dietary
intake is the only source of iodine; however, prenatal vitamins and
supplements also contain iodine and should be recommended to
womenof childbearing age. Use of iodized salt has been implemented
in several countries to reduce iodine deﬁciency. But only 70% of
householdsworldwide have access to iodized salt, and there is a need
to promote it extensively to achieve optimal intake [99]. Known
challenges to successful iodization includeuseof cheapernon-iodized
salt, limitation in quality control during salt production, compliancefailures, personal preferences, lack of awareness by households about
beneﬁts of iodized salt, market ﬂuctuations, and poor enforcement of
regulations mandating iodization [92]. Political commitment and salt
iodization legislation are also important to move ahead. There is a
need to identify optimal indicators for iodine deﬁciency, improved
screening of women of childbearing age, and monitoring iodine con-
tent in salt. Asmostpeople are limiting their salt intake to reduce their
risk of hypertension, other vehicles have to be explored to deliver
needed iodine to populations worldwide [92]. Taking these timely
steps, we may be able to prevent a majority of babies from the ill
outcomes associated with iodine deﬁciency.
10. Other opportunities for prevention
A recent review summarized a list of preventable birth defects
(Box 1) [100]. This prevention can be achieved by screening for
chromosome abnormalities and genetic disease, vaccinations,
screening for teratogenic infectious diseases such as human im-
munodeﬁciency virus and gonorrhea, and limiting or eliminating
the use of all known teratogenic drugs (e.g. anticoagulants, reti-
noids, and thalidomide). We should also be vigilant of new te-
ratogens. Parents should be informed of preconception diagnostic
choices including amniocentesis, chorionic villous sampling,
maternal serum monitoring, and ultrasound monitoring to di-
agnose identiﬁable genetic diseases and serious birth defects.
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such as maternal smoking, alcohol, caffeine, recreational drugs, and
obesity and overweight is needed in relation to their adverse effects
on pregnancy. While there are many prevention strategies to
reduce the incidence of birth defects worldwide, there is not
enough space allotted in this article for such extensive review.
11. Conclusion
Opportunities to prevent birth defects are abundant, but there
are also many challenges in the process. Pediatricians, researchers,
and public health practitioners in the ﬁeld of birth defects should
intensify prevention efforts, and undertake comprehensive and in-
tegrated efforts to accelerate the pace of prevention at a global scale
for preventable birth defects. Help and commitment from govern-
mental and non-governmental organizations, in a complementary
manner, is crucial to developing affordable and feasible prevention
programs. Only then can we achieve our goal of bringing current
rates of major preventable birth defects close to nil.
We have witnessed the global eradication of polio, which is
almost of the same magnitude as the current number of cases of
folic acid-preventable spina biﬁda. Similarly, an integrated
approach from the government and non-governmental agencies
has resulted in global eradication of smallpox. Lessons from suc-
cessful programs can be shared. Birth defects prevention is
achievable by combating socio-economic inequities and disparities
in health care for women of reproductive age. Need-driven and
impact-oriented approaches with improved education, prophy-
laxis, and prenatal care are needed. There exists an urgent need to
translate research ﬁndings to policy.
Now that developed countries are on their path towards success,
priority should now be placed on middle- and low-income coun-
tries. Funding for birth defects surveillance is urgently required to
plan and develop a functional primary prevention infrastructure for
future births. Over time, the health and economic returns, both at
micro and macro levels, would be signiﬁcant. Political will and
commitment by communities are an absolute necessity to initiate
and sustain birth defects prevention on a global scale.Practice points
 Global programs to prevent birth defects are an urgent
global health priority.
 Congenital rubella syndrome and folic acid-preventable
spina bifida and anencephaly could be eliminated from all
countries by implementing prevention programs already
shown to eliminate these birth defects in a few countries.
 Effective intervention programs must be developed and
implemented to prevent the three-fold increase in major
malformations among women with insulin-dependent
diabetes mellitus, as well as birth defects and develop-
mental disorders from in-utero exposure to alcohol.
 Valproic acid should be limited to persons with epilepsy
who have been shownnot to have control with at least one
other anticonvulsant, and should never be the first-line
treatment for epilepsy for women of reproductive age.
 Active, effective intervention programs promoting
optimal maternal birth age are needed to reduce the
current Down syndrome epidemic in developed countries
and to prevent the epidemic in countries that have yet to
experience it.
 There is a need to further intensify birth defects surveil-
lance and prevention programs in developing countries.
 Political will and commitment by communities are inte-
gral for birth defects prevention on a global scale.Conﬂict of interest statement
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